Nicole Onetto Net Worth

The estimated Net Worth of Nicole Onetto is at least $17.1 Tisíc dollars as of 15 June 2015. Nicole Onetto owns over 3,211 units of Sunesis Pharmaceuticals Inc stock worth over $17,083 and over the last 19 years he sold SNSS stock worth over $0. In addition, he makes $0 as Independent Director at Sunesis Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nicole Onetto SNSS stock SEC Form 4 insiders trading

Nicole has made over 1 trades of the Sunesis Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 3,211 units of SNSS stock worth $25,110 on 15 June 2015.

The largest trade he's ever made was exercising 3,211 units of Sunesis Pharmaceuticals Inc stock on 15 June 2015 worth over $25,110. On average, Nicole trades about 178 units every 0 days since 2005. As of 15 June 2015 he still owns at least 3,211 units of Sunesis Pharmaceuticals Inc stock.

You can see the complete history of Nicole Onetto stock trades at the bottom of the page.

Nicole Onetto biography

Dr. Nicole Onetto, M.D. is Independent Director sof the Company. Dr. Onetto is an expert in oncology drug development and translational research. She was most recently Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) from 2009 to 2016. Before her work at OICR, she was Senior Vice President and Chief Medical Officer at ZymoGenetics from 2005 to 2009. Prior to joining ZymoGenetics, she served as Executive Vice President Oncology, and then as Chief Medical Officer and Executive Vice President at OSI Pharmaceuticals from 2002 to 2005. With her team she led the worldwide registration program for Tarceva, one of the first targeted therapies approved for treating cancer patients. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb, Gilead Sciences, Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, and Immunex. At Bristol Myers Squibb, among other responsibilities, she was the worldwide project leader for Taxol. Dr. Onetto is currently a member of the board of Basilea Pharmaceutica, Sierra Oncology, and NBE Therapeutics. Previously she served for eleven years as a board member of ImmunoGen. Dr. Onetto received her M.D. from the University of Paris and a Master of Pharmacology from the University of Montréal.

How old is Nicole Onetto?

Nicole Onetto is 67, he's been the Independent Director of Sunesis Pharmaceuticals Inc since 2019. There are 2 older and 6 younger executives at Sunesis Pharmaceuticals Inc. The oldest executive at Sunesis Pharmaceuticals Inc is H. Ward Wolff, 71, who is the Director.

What's Nicole Onetto's mailing address?

Nicole's mailing address filed with the SEC is SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, STE. 400, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sunesis Pharmaceuticals Inc

Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.

What does Sunesis Pharmaceuticals Inc do?

Complete history of Nicole Onetto stock trades at Immunogen, Sierra Oncology Inc a Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc executives and stock owners

Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Adam Craig,
  Executive Vice President - Development, Chief Medical Officer
• Stephen Ketchum,
  Director
• David Stump,
  Independent Director
• Homer Pearce,
  Independent Director
• Nicole Onetto,
  Independent Director
• Matthew Fust,
  Independent Director
• Steve Carchedi,
  Independent Director
• H. Ward Wolff,
  Director
• Tina Gullotta,
  Principal Accounting Officer, Vice President - Finance
• Dayton Misfeldt,
  Chief Executive Officer, Principal Financial Officer, Secretary, Director
• James Young,
  Non-Executive Independent Chairman of the Board
• Eric Bjerkholt,
  EVP, CFO & Corp. Secretary
• Geoffrey M. Parker,
  Director
• Steven B Ketchum,
  Director
• Daniel N Jr Swisher,
  President and CEO
• Oncology Impact Management ...,
  
• William P. Quinn,
  See Remarks
• Judith A. Fox,
  See Remarks
• Patrick J Kerins,
  10% owner
• Ryan D Drant,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Equity Opportunities Fund, ...,
  
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Helen Susan Kim,
  Director
• Joseph I De Pinto,
  EVP, CCO
• Biopharma Partners Iii Lpal...,
  
• Equity Opportunities Fund, ...,
  
• Robert Scott Mc Dowell,
  Vice President, Research
• Edward Hurwitz,
  Director
• Dominique Semon,
  10% owner
• Biopharma Partners Iii Lpal...,
  
• Iii Eugene A Trainor,
  10% owner
• Charles M Linehan,
  10% owner
• Equity Opportunities Fund, ...,
  
• Pincus Equity Partners Lpwa...,
  
• Valerie L Pierce,
  Sr. VP, GC & Corp. Secretary
• Anthony B Evnin,
  Director
• Steven D Goldby,
  Director
• James A Wells,
  Director
• Stephen P A Fodor,
  Director
• Idec Incbiogen Idec Ma Inc ...,
  
• Pincus Equity Partners Lpwa...,
  
• Daniel C Md Adelman,
  Senior VP,Drug Discovery & Dev
• Ixmayfield Ix Management Ll...,
  
• Jonathan S Leff,
  Director
• Daryl B Winter,
  SVP,Gen Counsel/Corp Secretary
• Capital Iv, Lp Aisling Capi...,